Andreas Tiede

TL;DR: The management of AVWS is reviewed with an overview on the currently available evidence and additional considerations for typical treatment situations, including treatment options including desmopressin, VWF-containing concentrates, intravenous immunoglobulin, plasmapheresis or recombinant factor VIIa.

TL;DR: Acquired hemophilia A is a rare disease resulting from autoantibodies against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and severe.

TL;DR: This first human dose trial in patients with hemophilia B investigated the safety and pharmacokinetic properties of a single IV dose of N9-GP, a recombinant FIX molecule with a prolonged half-life which has the potential to reduce dosing frequency while providing effective treatment of bleeding episodes with a single dose.

TL;DR: Presenting FVIII and inhibitor concentration are potentially useful to tailor IST in AHA and are associated with a lower rate of complete remission and decreased survival.

TL;DR: Both the safety and improved pharmacokinetics of rIX-FP are demonstrated, indicating this new product with extended half-life as possibly able to control and prevent bleeding with less frequent injection.